-free survival and overall survival data are not mature. Serious adverse events occurred in 4 patients - one patient had grade 3 bronchopulmonary hemorrhage, 3 patients had grade 4 neutropenia and/or thrombocytopenia. There were no treatment-related deaths
Search Results
CLO20-054: A Phase 2 Trial of Nivolumab and Temozolomide in Advanced Neuroendocrine Tumors (NETs): Interim Efficacy Analysis
Dwight H. Owen, Lai Wei, Ashima Goyal, Ye Zhou, Sheryl-Ann Suffren, Rajani Jacob, Carly Pilcher, Gregory A. Otterson, Claire F. Verschraegen, Manisha H. Shah, and Bhavana Konda
Will Biosimilars Gain Momentum?
Bradford R. Hirsch and Gary H. Lyman
recombinant human G-CSF made by a subsidiary of Teva Pharmaceuticals that has been approved by the FDA, because the agent has been shown to reduce the duration of severe neutropenia in patients with nonmyeloid malignancies undergoing cancer chemotherapy
Counterpoint: Routine Anti-Bacterial Prophylaxis Is Not Indicated in Neutropenic Patients With Hematological Malignancies
Michael Kleinberg
– 452 . 15 Pizzo PA Hathorn JW Hiemenz J . A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia . N Engl J Med 1986 ; 315 : 552 – 558 . 16 Winston DJ
Chronic Myeloid Leukemia/Myelofibrosis: TKI Therapy and Toxicity Management
Presented by: Gabriela S. Hobbs and Christopher Bell
preferred. Imatinib should be paused in cases of hematologic toxicities such as neutropenia or thrombocytopenia. After recovery from these toxicities, it can be resumed at the initial dose for first incidences, but in cases of recurrence, the dose should
Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients With Advanced Cancer
Apostolia M. Tsimberidou, Alexandra M. Adamopoulos, Yang Ye, Sarina Piha-Paul, Filip Janku, Siqing Fu, David Hong, Gerald S. Falchook, Aung Naing, Jennifer Wheler, Adoneca Fortier, Razelle Kurzrock, and Kenneth R. Hess
regimens; (4) any other grade 3 nonhematologic toxicity, including symptoms/signs of vascular leak or cytokine release syndrome but excluding alopecia; (5) grade 4 thrombocytopenia; (6) any grade 4 neutropenia lasting more than 7 days (as defined by the NCI
CDK4/6 Inhibitors for Advanced Hormone Receptor–Positive Breast Cancer, 2019 and Beyond
Rachel M. Layman
. Neutropenia of all grades was observed in 88.5% of patients, 5 similar to the approximately 80% reported in PALOMA-2 and PALOMA-3. 2 , 3 Interestingly, there was less grade 3/4 neutropenia in this study (41.5% 5 vs 66.4% and 65% in PALOMA-2 2 and PALOMA-3
The Costs of Drugs Used to Treat Myelodysplastic Syndromes Following National Comprehensive Cancer Network Guidelines
Peter L. Greenberg, Leon E. Cosler, Salvatore A. Ferro, and Gary H. Lyman
descriptive review . Nat Clin Pract Oncol 2007 ; 4 : 643 – 656 . 29. Kuderer NM Dale DC Crawford J . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer 2006 ; 106 : 2258 – 2266 . 30
Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology
Lindsey Robert Baden, Sankar Swaminathan, Michael Angarone, Gayle Blouin, Bernard C. Camins, Corey Casper, Brenda Cooper, Erik R. Dubberke, Ashley Morris Engemann, Alison G. Freifeld, John N. Greene, James I. Ito, Daniel R. Kaul, Mark E. Lustberg, Jose G. Montoya, Ken Rolston, Gowri Satyanarayana, Brahm Segal, Susan K. Seo, Shmuel Shoham, Randy Taplitz, Jeffrey Topal, John W. Wilson, Karin G. Hoffmann, and Courtney Smith
There is an increased risk of infection in patients with cancer that results in higher morbidity and mortality. In certain instances, the cancer itself can predispose patients to severe or recurrent infections. Neutropenia has been recognized as a major
CLO22-084: Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Previously Treated Metastatic Colorectal Cancer: A Multicenter Retrospective Analysis With Focus on Elderly Patients Subgroup
Carlo Signorelli, Federica Zoratto, Donatello Gemma, Rosa Saltarelli, Maria Grazia Morandi, Roberta Grande, Gian Paolo Spinelli, Salvatore De Marco, Isabella Sperduti, Mario Giovanni Chilelli, Anna Ceribelli, and Enzo Maria Ruggeri
, 40% treated with REG and 60% with FTD/TPI, were also analyzed. In this subgroup, the most common grade 3/4 AE was hand-foot syndrome (33.3%) vs neutropenia (42.8%), the mOS was 3.5 vs 5 months and the best response was stable disease (35.7% vs 14
Biosimilars: Are They Ready for Primetime in the United States?
Bradford R. Hirsch and Gary H. Lyman
, providing an excellent example of the strengths and weaknesses of the field. These agents are administered subcutaneously, starting 1 to 3 days after completion of cytotoxic therapy to reduce the severity and duration of neutropenia and the risk of febrile
